Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia
Samar J. Almehmadi, Amani M.R. Alsaedi, Marwa F. Harras, et al.
Bioorganic Chemistry (2021) Vol. 117, pp. 105431-105431
Closed Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

A review on the role of cyclin dependent kinases in cancers
Soudeh Ghafouri‐Fard, Tayyebeh Khoshbakht, Bashdar Mahmud Hussen, et al.
Cancer Cell International (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 70
Advances in pyrazolo[1,5-a]pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment
Terungwa H. Iorkula, Osasere Jude-Kelly Osayawe, Daniel A. Odogwu, et al.
RSC Advances (2025) Vol. 15, Iss. 5, pp. 3756-3828
Open Access
Discovery of pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine derivatives as novel CDK2 inhibitors: synthesis, biological and molecular modeling investigations
Ibrahim F. Nassar, Mohammed Taha Abdel Aal, Wael A. El‐Sayed, et al.
RSC Advances (2022) Vol. 12, Iss. 23, pp. 14865-14882
Open Access | Times Cited: 33
Indenyl-thiazole and indenyl-formazan derivatives: Synthesis, anticancer screening studies, molecular-docking, and pharmacokinetic/ molin-spiration properties
Ghaidaa H. Alfaifi, Thoraya A. Farghaly, Magda H. Abdellattif
PLoS ONE (2023) Vol. 18, Iss. 3, pp. e0274459-e0274459
Open Access | Times Cited: 14
Synthesis, antitumor activity, antimicrobial evaluation and molecular docking studies of some hydrazone, 1,3,4-oxadiazole, 1,2,4-triazole and pyrazole derivatives bearing nicotinoyl moiety
Abdel‐Rahman Farghaly, Saleh A. Ahmed, Khatib Sayeed Ismail, et al.
Results in Chemistry (2024) Vol. 7, pp. 101474-101474
Open Access | Times Cited: 5
Synthesis, biological evaluation, and in silico studies of new CDK2 inhibitors based on pyrazolo[3,4-d]pyrimidine and pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold with apoptotic activity
Asmaa A. Mandour, Ibrahim F. Nassar, Mohammed Taha Abdel Aal, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 1957-1973
Open Access | Times Cited: 24
Discovery of novel indene-based hybrids as breast cancer inhibitors targeting Hsp90: Synthesis, bio-evaluation and molecular docking study
Amal M. Alosaimy, Amr S. Abouzied, Amani M.R. Alsaedi, et al.
Arabian Journal of Chemistry (2023) Vol. 16, Iss. 4, pp. 104569-104569
Open Access | Times Cited: 13
Design, synthesis, antimicrobial screening and molecular modeling of novel 6,7 dimethylquinoxalin-2(1H)-one and thiazole derivatives targeting DNA gyrase enzyme
Raghad M. Alqurashi, Thoraya A. Farghaly, Rehab Sabour, et al.
Bioorganic Chemistry (2023) Vol. 134, pp. 106433-106433
Closed Access | Times Cited: 11
BF3-Mediated Acetylation of Pyrazolo[1,5-a]pyrimidines and Other π-Excedent (N-Hetero)arenes
Sandra‐L. Aranzazu, Alexis Tigreros, Andres Arias-Gómez, et al.
The Journal of Organic Chemistry (2022) Vol. 87, Iss. 15, pp. 9839-9850
Closed Access | Times Cited: 17
Novel 6,7,8-trihydrobenzo[6',7']cyclohepta[2',1'-e]pyrazolo[2,3-a]pyrimidine derivatives as Topo IIα inhibitors with potential cytotoxic activity
Thoraya A. Farghaly, Hanan Gaber Abdulwahab, Hanadi Y. Medrasi, et al.
Bioorganic Chemistry (2022) Vol. 128, pp. 106043-106043
Closed Access | Times Cited: 17
A patent review of anticancer CDK2 inhibitors (2017–present)
Mohamed A. Said, Mohamed A. Abdelrahman, Mohammed A. S. Abourehab, et al.
Expert Opinion on Therapeutic Patents (2022) Vol. 32, Iss. 8, pp. 885-898
Closed Access | Times Cited: 15
Organocatalytic [3 + 2] Cycloaddition Reaction: Synthesis of Fully Decorated Sulfonyl-1,2,3-Triazolyl Pyrimidines as Potent Anticancer and EGFR Inhibitors
Jagan Mohan Reddy Velidandla, Shiva Kumar Koppula
Polycyclic aromatic compounds (2023) Vol. 44, Iss. 4, pp. 2675-2687
Closed Access | Times Cited: 8
Novel purine derivatives as selective CDK2 inhibitors with potential anticancer activities: Design, synthesis and biological evaluation
Alpesh D. Shah, Nishith Teraiya, Jignesh H. Kamdar, et al.
Bioorganic Chemistry (2024) Vol. 153, pp. 107841-107841
Closed Access | Times Cited: 2
Advances in Cancer Therapy: A Comprehensive Review of CDK and EGFR Inhibitors
Mohammed Hawash
Cells (2024) Vol. 13, Iss. 19, pp. 1656-1656
Open Access | Times Cited: 2
Design, synthesis, cytotoxicity, and molecular docking studies of novel thiazolyl–hydrazone derivatives as histone lysine acetyl‐transferase inhibitors and apoptosis inducers
Eman M. H. Abbas, Thoraya A. Farghaly, Rehab Sabour, et al.
Archiv der Pharmazie (2022) Vol. 355, Iss. 7
Closed Access | Times Cited: 13
Synthesis, anticancer evaluation, and molecular modeling study of new 2-(phenylamino)pyrazolo[1,5-a]pyrimidine analogues
Omer A. Azher, Aisha Hossan, Rami Adel Pashameah, et al.
Arabian Journal of Chemistry (2022) Vol. 16, Iss. 1, pp. 104437-104437
Open Access | Times Cited: 13
Maintaining Drosha expression with Cdk5 inhibitors as a potential therapeutic strategy for early intervention after TBI
Lu Huang, Xia Li, Tiejian Nie, et al.
Experimental & Molecular Medicine (2024) Vol. 56, Iss. 1, pp. 210-219
Open Access | Times Cited: 1
Unveiling the promise of pyrimidine-modified CDK inhibitors in cancer treatment
Rahul Dubey, Rahul Makhija, Anushka Sharma, et al.
Bioorganic Chemistry (2024) Vol. 149, pp. 107508-107508
Closed Access | Times Cited: 1
Catalyst and base free aza-Michael addition reaction: Synthesis of poly-substituted 4-pyrazole based benzopyrans
Tapaswini Das, Seetaram Mohapatra, Nilima Priyadarsini Mishra, et al.
Tetrahedron Letters (2022) Vol. 96, pp. 153762-153762
Closed Access | Times Cited: 8
Development of pyrazolo[1,5-a]pyrimidine derivatives: Synthesis, anticancer activity and docking study
Omneya M. El-Bakry, Marwa F. Harras, Mohamed M. Elsebaei, et al.
Azhar International Journal of Pharmaceutical and Medical Sciences/Azhar International Journal of Pharmaceutical and Medical Sciences (2023)
Open Access | Times Cited: 3
The development of an unexpected Cu(I)‐pyrazolo pyrimidine‐based complex: Synthesis, spectroscopic characterizations, and biological activity
Hemmat A. Elbadawy, B.A. Abd-El-Nabey, Ali El‐Dissouky, et al.
Applied Organometallic Chemistry (2022) Vol. 36, Iss. 10
Closed Access | Times Cited: 5
Synthesis of tricyclic and tetracyclic benzo[6,7]cycloheptane derivatives linked morpholine moiety as CDK2 inhibitors
Thoraya A. Farghaly, Eman M. H. Abbas, Mariam A. Al‐Sheikh, et al.
Drug Development Research (2023) Vol. 84, Iss. 6, pp. 1127-1141
Closed Access | Times Cited: 2
Synthesis, anti-leukemia activity, and molecular docking of novel 3,16-androstenedione derivatives
Dongjie Chen, Jiaying Huang, Shanshan Xiao, et al.
Steroids (2023) Vol. 199, pp. 109290-109290
Closed Access | Times Cited: 2
Cyclin-dependent kinase 2 (CDK2)
Ghada F. Elmasry
Elsevier eBooks (2023), pp. 51-62
Closed Access | Times Cited: 2
Design and Synthesis of New bis-oxindole and Spiro(triazole-oxindole) as CDK4 Inhibitors with Potent Anti-breast Cancer Activity
Thoraya A. Farghaly, Rami Adel Pashameah, Abrar Bayazeed, et al.
Medicinal Chemistry (2023) Vol. 20, Iss. 1, pp. 63-77
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top